Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

• Published in: Journal of nanobiotechnology 2020-10, Vol.18 (1), p.145-25, Article 145
• Main Authors: Xu, You, Liu, Hongmei, Song, Lei
• Format: Article
• Language: English
• Subjects: Administration, Inhalation; Analysis; Animal models; Animals; Antioxidants; Antioxidants - pharmacology; Bioavailability; Chronic obstructive pulmonary disease; Delayed-Action Preparations; Development and progression; Disease Progression; Drug Carriers - pharmacology; Drug delivery; Drug Delivery Systems; Drug Liberation; Drug therapy; Drug therapy, Combination; Drugs; Health aspects; Humans; Lung - drug effects; Lung diseases; Lung diseases, Obstructive; Microparticles; Nanocomposite microparticles; Nanoparticles; Nanoparticles - therapeutic use; Nanotechnology; Nutrients; Obstructive lung disease; Oxidation; Oxidative stress; Oxidative Stress - drug effects; Pathogenesis; Pharmacokinetics; Pulmonary Disease, Chronic Obstructive - drug therapy; Review; Technology application; Vehicles
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-020-00703-5

Oxidative stress is significantly involved in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). Combining antioxidant drugs or nutrients results in a noteworthy therapeutic value in animal models of COPD. However, the benefits have not been reproduced in clinical applications, this may be attributed to the limited absorption, concentration, and half-life of exogenous antioxidants. Therefore, novel drug delivery systems to combat oxidative stress in COPD are needed. This review presents a brief insight into the current knowledge on the role of oxidative stress and highlights the recent trends in novel drug delivery carriers that could aid in combating oxidative stress in COPD. The introduction of nanotechnology has enabled researchers to overcome several problems and improve the pharmacokinetics and bioavailability of drugs. Large porous microparticles, and porous nanoparticle-encapsulated microparticles are the most promising carriers for achieving effective pulmonary deposition of inhaled medication and obtaining controlled drug release. However, translating drug delivery systems for administration in pulmonary clinical settings is still in its initial phases.